Search Results

Sir William Osler Scientists have long sought to discover a “golden bullet” that would cure every disease

Healthy Adults Crinetics Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business

We got a little busy with all the major events at Dr.GPCR, so our weekly news looks slightly different

microscopy for GPCR research and drug discovery in endocrinology and metabolism Reviews, GPCRs, and more Butyrate

MacDonald as Chief Business Officer.

Research Hospital adds $13 million project to Research Collaboratives Program AIRSUPRA® (albuterol/budesonide

Biologic Trevena Announces Acceptance of Abstract Examining the Use of OLINVYK in Patients with Acute Burn

CryoEM structures of adhesion in GPCR CD97: Filling in some of the gaps GPCR Activation and Signaling Butyrate receptor NTR-1's Essential Contribution to Asymmetric Mating Between Two Sibling Nematode Species: Bursaphelenchus for type 2 diabetes mellitus therapy Industry News OMass Therapeutics Welcomes Melissa Faris as Chief Business

and more Current strategic trends in drug discovery: the present as prologue Industry News Exscientia Business

Design and Pharmacology Faculty of Health and Medical Sciences Octant Apprentice Head of Human Resource Business

and Pharmacology Faculty of Health and Medical Sciences NEW Octant Apprentice Head of Human Resource Business

Immuno-Oncology, Domain Therapeutics, Presents Groundbreaking Advancements at ESMO 2023 Novo Nordisk to Buy Conference and Exhibition June 2 - 7, 2024 | Chemotactic Cytokines GPCR Jobs Head of Human Resource Business

Conference and Exhibition June 2 - 4, 2024 | Chemotactic Cytokines GPCR Jobs NEW Head of Human Resource Business

mGlu2 NAM Cognition Program Receives €4 Million Grant Confo Therapeutics Appoints Stephen Dowd As Chief Business

characteristics of Nbs are: Small size and solubility: Their small size and soluble nature make them ideal building Nature, 504(7478), 101–106. https://doi.org/10.1038/nature12735 Burg, J. S., Ingram, J.

transmembrane proteins characterization in drug discovery Confo Therapeutics Appoints Stephen Dowd As Chief Business

patient dosed with oral immunotherapy drug Trevena Reports Second Quarter 2023 Results and Provides Business

Dosing of the First Patient in a Phase I/IIa Trial with Cancer Immunotherapy Drug HTL0039732 Exscientia Business

Devki D Sukhtankar and Pina M Cardarelli's research: Burixafor Hydrobromide (GPC-100) effects on hematopoietic Profile Endogenous Human Adenosine A3 Receptor Expression Pharmacokinetics and Pharmacodynamics of Burixafor

Bryan Roth's work on "Built-in functional selectivity in neurons is mediated by the neuronal protein, Built-in functional selectivity in neurons is mediated by the neuronal protein, GINIP. Sosei Heptares Acquires Idorsia’s Pharmaceuticals Business in Japan and APAC (ex-China), Accelerating

Welcome, GPCR buffs! Join us for our weekly round-up of GPCR News. Congratulations to our Dr.

hook-like conformation, whereas the chemokine antagonist ([5P7]CCL5) folds into a helical shape due to bulky : a shallow binding mode within the transmembrane binding site and limited interaction with the 7TM bundle

Reduces the Rate of Lung Function Decline in Patients with Idiopathic Pulmonary Fibrosis Exscientia Business

Hi GPCR buffs 👋! This week's GPCR papers feature a publication from Dr. Marta Filizola.

Stay tuned for the latest buzz on GPCRs. This week's GPCR papers feature publications from Drs.

, O’Boyle, de Graaf & Bender, 2021) and 4) limit of input data can lead to a phenomenon called “the burden

2023 GPCR Events, Meetings, and Webinars NEW FREE 7th ERNEST GPCR zoominar (April 20, 2023) SLAS 2023 Building

SLAS 2023 Building Biology in 3D Symposium.

GPCR Activation and Signaling Butyrate potentiates Enterococcus faecalis lipoteichoic acid-induced inflammasome ecosystem - leadXpro and InterAx part of Fujitsu CaaS GPCR Events, Meetings, and Webinars SLAS 2023 Building

Exscientia Business and Financial Update for the Full Year 2022. Pharma (March 31, 2023) NEW FREE Workshop - Challenges in GPCR Drug Discovery (March 31, 2023) SLAS 2023 Building